Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Pharmaceutical Preparations

Cycle Group Holdings Limited to acquire Applied Therapeutics, Inc.

Announced Dec 11, 2025 · Closed Feb 3, 2026

Deal value$13MEV $1M
Premium—To unaffected price
EV / Adj. EBITDA—0.8x EV / Revenue
ConsiderationAll cash$0.09 per share

Transaction

Acquirer
Cycle Group Holdings Limited
Target
Applied Therapeutics, Inc. (APLT)
Buyer type
Strategic
Offer price per share
$0.09
Enterprise value
$1M
Status
Closed Feb 3, 2026

Deal protections

Break fee (target pays)
—
Reverse fee (buyer pays)
—
Go-shop
No-shop
Financing
No financing condition

Advisors

To the acquirer
Not disclosed
To the target
Aquilo Partners

Sector context · Healthcare

Comparable deals
97 in the prior 24 months
Premium
Sector median 60.0%
EV / Adj. EBITDA
Sector median 14.5x
Break fee
Sector median 3.3%

Timeline

  1. AnnouncedDec 11, 2025
  2. Tender offerDec 29, 2025
  3. ClosedFeb 3, 2026
Sources
  • SC14D9C (EX-99.2) · Dec 12, 2025
  • 8-K · Dec 12, 2025

Adj. EBITDA is operating income + D&A + impairment, restructuring, deal costs and stock compensation, less any large gain on a sale, last twelve months, from the target's filings. Calculated by Castle, so it can differ from a bank's adjusted figure.

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.